187 related articles for article (PubMed ID: 25692405)
1. Whole-exome DNA sequence analysis of Brca2- and Trp53-deficient mouse mammary gland tumours.
Francis JC; Melchor L; Campbell J; Kendrick H; Wei W; Armisen-Garrido J; Assiotis I; Chen L; Kozarewa I; Fenwick K; Swain A; Smalley MJ; Lord CJ; Ashworth A
J Pathol; 2015 Jun; 236(2):186-200. PubMed ID: 25692405
[TBL] [Abstract][Full Text] [Related]
2. Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.
Bowman-Colin C; Xia B; Bunting S; Klijn C; Drost R; Bouwman P; Fineman L; Chen X; Culhane AC; Cai H; Rodig SJ; Bronson RT; Jonkers J; Nussenzweig A; Kanellopoulou C; Livingston DM
Proc Natl Acad Sci U S A; 2013 May; 110(21):8632-7. PubMed ID: 23657012
[TBL] [Abstract][Full Text] [Related]
3. Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.
Pfefferle AD; Agrawal YN; Koboldt DC; Kanchi KL; Herschkowitz JI; Mardis ER; Rosen JM; Perou CM
Dis Model Mech; 2016 Jul; 9(7):749-57. PubMed ID: 27149990
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
[TBL] [Abstract][Full Text] [Related]
5. Somatic structural rearrangements in genetically engineered mouse mammary tumors.
Varela I; Klijn C; Stephens PJ; Mudie LJ; Stebbings L; Galappaththige D; van der Gulden H; Schut E; Klarenbeek S; Campbell PJ; Wessels LF; Stratton MR; Jonkers J; Futreal PA; Adams DJ
Genome Biol; 2010; 11(10):R100. PubMed ID: 20942901
[TBL] [Abstract][Full Text] [Related]
6. DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas.
Kamieniak MM; Muñoz-Repeto I; Rico D; Osorio A; Urioste M; García-Donas J; Hernando S; Robles-Díaz L; Ramón Y Cajal T; Cazorla A; Sáez R; García-Bueno JM; Domingo S; Borrego S; Palacios J; van de Wiel MA; Ylstra B; Benítez J; García MJ
Br J Cancer; 2013 Apr; 108(8):1732-42. PubMed ID: 23558894
[TBL] [Abstract][Full Text] [Related]
7. Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.
Ong PY; Poon SL; Tan KT; Putti TC; Ow SGW; Chen SJ; Chen CH; Lee SC
Gynecol Oncol; 2019 Nov; 155(2):275-279. PubMed ID: 31481248
[TBL] [Abstract][Full Text] [Related]
8. Loss of Fbxw7 Impairs Development of and Induces Heterogeneous Tumor Formation in the Mouse Mammary Gland.
Onoyama I; Nakayama S; Shimizu H; Nakayama KI
Cancer Res; 2020 Dec; 80(24):5515-5530. PubMed ID: 33234509
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.
Hay T; Matthews JR; Pietzka L; Lau A; Cranston A; Nygren AO; Douglas-Jones A; Smith GC; Martin NM; O'Connor M; Clarke AR
Cancer Res; 2009 May; 69(9):3850-5. PubMed ID: 19383921
[TBL] [Abstract][Full Text] [Related]
10. A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer.
Hollern DP; Contreras CM; Dance-Barnes S; Silva GO; Pfefferle AD; Xiong J; Darr DB; Usary J; Mott KR; Perou CM
Breast Cancer Res Treat; 2019 Feb; 174(1):143-155. PubMed ID: 30484104
[TBL] [Abstract][Full Text] [Related]
11. Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers.
Tumiati M; Munne PM; Edgren H; Eldfors S; Hemmes A; Kuznetsov SG
Oncogene; 2016 Sep; 35(35):4601-10. PubMed ID: 26820992
[TBL] [Abstract][Full Text] [Related]
12. Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa.
Staff S; Isola JJ; Johannsson O; Borg A; Tanner MM
Br J Cancer; 2001 Oct; 85(8):1201-5. PubMed ID: 11710835
[TBL] [Abstract][Full Text] [Related]
13. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
14. Responsiveness of
Alothman SJ; Wang W; Goerlitz DS; Islam M; Zhong X; Kishore A; Azhar RI; Kallakury BV; Furth PA
Cancer Prev Res (Phila); 2017 Apr; 10(4):244-254. PubMed ID: 28283467
[TBL] [Abstract][Full Text] [Related]
15. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
Stefansson OA; Jonasson JG; Johannsson OT; Olafsdottir K; Steinarsdottir M; Valgeirsdottir S; Eyfjord JE
Breast Cancer Res; 2009; 11(4):R47. PubMed ID: 19589159
[TBL] [Abstract][Full Text] [Related]
16. siRNA screening identifies differences in the Fanconi anemia pathway in BALB/c-Trp53+/- with susceptibility versus C57BL/6-Trp53+/- mice with resistance to mammary tumors.
Böhringer M; Obermeier K; Griner N; Waldraff D; Dickinson E; Eirich K; Schindler D; Hagen M; Jerry DJ; Wiesmüller L
Oncogene; 2013 Nov; 32(48):5458-70. PubMed ID: 23435420
[TBL] [Abstract][Full Text] [Related]
17. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F
Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859
[TBL] [Abstract][Full Text] [Related]
18. Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients.
Silva FC; Lisboa BC; Figueiredo MC; Torrezan GT; Santos EM; Krepischi AC; Rossi BM; Achatz MI; Carraro DM
BMC Med Genet; 2014 May; 15():55. PubMed ID: 24884479
[TBL] [Abstract][Full Text] [Related]
19. Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.
Valarmathi MT; Sawhney M; Deo SSV; Shukla NK; Das SN
Hum Mutat; 2004 Feb; 23(2):205. PubMed ID: 14722926
[TBL] [Abstract][Full Text] [Related]
20. Ovarian Cancer-Specific
Schouten PC; Richters L; Vis DJ; Kommoss S; van Dijk E; Ernst C; Kluin RJC; Marmé F; Lips EH; Schmidt S; Scheerman E; Prieske K; van Deurzen CHM; Burges A; Ewing-Graham PC; Dietrich D; Jager A; de Gregorio N; Hauke J; du Bois A; Nederlof PM; Wessels LF; Hahnen E; Harter P; Linn SC; Schmutzler RK
Clin Cancer Res; 2021 Dec; 27(23):6559-6569. PubMed ID: 34593530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
